ACG introduces desiccant-enabled cold-form laminate for pharmaceutical applications in India

A key distinction of DryPod™ lies in its patent-clean architecture

ACG, the world’s most comprehensive provider of solid-dosage and packaging technologies, has unveiled DryPod™, an advanced desiccant-integrated cold-form laminate designed to safeguard drug molecules that are highly susceptible to moisture.

DryPod™ represents a significant leap for pharmaceutical manufacturers who have long faced issues such as restricted material availability, inflexible designs, and performance challenges with existing desiccant cold-form systems.

Ensuring moisture protection is essential for maintaining drug potency throughout distribution and retail storage. Yet, current commercial solutions depend primarily on a single co-extrusion-based patented technology. This reliance creates limitations, including narrow equipment compatibility, dependence on specific lidding materials, prolonged procurement timelines, limited supplier diversity, and inconsistent technical support across regions.

DryPod™ eliminates these constraints and empowers pharmaceutical companies to innovate freely while maintaining product protection, regulatory adherence, and manufacturing efficiency.

In contrast to conventional co-extruded formats, DryPod™ is developed through a proprietary lamination-driven process that ensures reliable performance across all commonly used blister-forming platforms. This approach removes the need for specialised machine upgrades or process adjustments, enabling manufacturers to adopt DryPod™ seamlessly on existing blister lines. Additionally, the laminate is compatible with any PE-sealable lidding foil, helping reduce supply-chain dependence and enabling agile global sourcing.

One of DryPod’s™ most notable attributes is its patent-clean configuration. Built with zero overlap with active patents governing desiccant co-extrusion technologies, DryPod™ provides manufacturers with complete legal certainty, supporting supplier diversification, production scale-up, and geographic expansion without intellectual-property risks.